BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Spravato (Esketamine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Spravato (Esketamine)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07324057-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Spravato (Esketamine): Phase na readout est. (NCT07324057)
DESCRIPTION:Spravato (Esketamine)\, phase na.\nStudy: The Effects of Preope
 rative Intranasal Administration of Dexmedetomidine and Esketamine on Nega
 tive Postoperative Behavioral Changes in Children With Autism Spectrum Dis
 order\nEstimated primary completion: 1 February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/esketamine#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07324057
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06278779-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Spravato (Esketamine): Phase 4 readout est. (NCT06278779)
DESCRIPTION:Spravato (Esketamine)\, phase 4\, Major Depressive Disorder.\nS
 tudy: Comparative Effectiveness Study of Two Forms of Ketamine for Treatme
 nt-resistant Depression\nEstimated primary completion: April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/esketamine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06278779
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934901-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Spravato (Esketamine): Phase 4 readout est. (NCT07934901)
DESCRIPTION:Spravato (Esketamine)\, phase 4.\nStudy: Intranasal Esketamine-
 dexmedetomidine Combination in Patients With Postherpetic Neuralgia\nEstim
 ated primary completion: November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/esketamine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07934901
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103760-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Spravato (Esketamine): Phase 4 readout est. (NCT06103760)
DESCRIPTION:Spravato (Esketamine)\, phase 4\, Major Depressive Disorder.\nS
 tudy: Positioning of Esketamine Treatment in the Real-world Management of 
 Depression\nEstimated primary completion: 15 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/esketamine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06103760
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07716098-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20281227
DTEND;VALUE=DATE:20281228
SUMMARY:Spravato (Esketamine): Phase 3 readout est. (NCT07716098)
DESCRIPTION:Spravato (Esketamine)\, phase 3\, Major Depressive Disorder.\nS
 tudy: A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Part
 icipants With Treatment-resistant Depression\nEstimated primary completion
 : 27 December 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 sketamine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07716098
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639099-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Spravato (Esketamine): Phase 4 readout est. (NCT07639099)
DESCRIPTION:Spravato (Esketamine)\, phase 4.\nStudy: Intranasal Esketamine-
 dexmedetomidine Combination and Postpartum Depression\nEstimated primary c
 ompletion: October 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/esketamine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07639099
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06713616-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Spravato (Esketamine): Phase 3 readout est. (NCT06713616)
DESCRIPTION:Spravato (Esketamine)\, phase 3.\nStudy: PCORI Comparative Effe
 ctiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study\nEsti
 mated primary completion: 31 December 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/esketamine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06713616
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227454-800@assetmemo.bio
DTSTAMP:20261121T004050Z
DTSTART;VALUE=DATE:20310409
DTEND;VALUE=DATE:20310410
SUMMARY:Spravato (Esketamine): Phase 3 readout est. (NCT07227454)
DESCRIPTION:Spravato (Esketamine)\, phase 3\, Major Depressive Disorder.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of Esketamine for Reduct
 ion of Symptoms of Major Depressive Disorder\nEstimated primary completion
 : 9 April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/esket
 amine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07227454
URL:https://assetmemo.bio/drug/esketamine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
